The persistence of the E7 oncoprotein in transformed cells in human papillomavirus (HPV)-associated cervical cancer provides a tumourspecific antigen to which immunotherapeutic strategies may be directed. Self-replicating RNA (replicon) vaccine vectors derived from the flavivirus Kunjin (KUN) have recently been reported to induce T-cell immunity. Here, we report that inclusion of a CTL epitope of HPV16 E7 protein into a polyepitope encoded by a KUN vector induced E7-directed T-cell responses and protected mice against challenge with an E7-expressing epithelial tumour. We found replicon RNA packaged into virus-like particles to be more effective than naked replicon RNA or plasmid DNA constructed to allow replicon RNA transcription in vivo. Protective immunity was induced although the E7 CTL epitope was subdominant in the context of other CTL epitopes in the polyepitope. The results demonstrate the efficacy of the KUN replicon vector system for inducing protective immunity directed towards a virally encoded human tumour-specific antigen, and for inducing multi-epitopic CTL responses.
Introduction
Human papillomaviruses (HPVs) are associated with a variety of squamous cell cancers (zur Hausen, 2002) . HPV is detected in ca. 95% of cervical carcinomas, particularly the 'high-risk' oncogenic genotypes HPV 16 and 18. The protein products of the HPV genes E7 and E6 are principally responsible for transforming cervical epithelial cells, by binding to and abrogating the cell-cycle control functions of cellular retinoblastoma protein and p53, respectively (Scheffner et al., 1993; Slebos et al., 1994) . This mode of action requires that E7 and E6 proteins persist in order for the cells to remain transformed (von Knebel et al., 1994) , and thus these viral proteins function as tumour-associated antigens (TAAs), to which preclinical and clinical immunotherapeutic strategies are being directed. Cytotoxic T lymphocytes (CTLs) kill tumour cells displaying epitopes derived from TAAs displayed on the tumour cell surface in conjunction with major histocompatibility (MHC) molecules. The CTL response to E7 protein induced by several vaccine candidates, including peptides (Feltkamp et al., 1995) , plasmid DNA (Ji et al., 1999) , viral vectors (Lin et al., 1996) , recombinant fusion proteins (Chu et al., 2000) , and chimeric virus-like particles (VLPs) (Chu et al., 2000; Greenstone et al., 1998 ) is a determinant of HPV-associated disease outcome in experimental murine tumours expressing the HPV16 E7 gene (Feltkamp et al., 1995) . Human MHC restricted E7 CTL epitopes identified in human leucocyte antigen (HLA) transgenic mice have successfully primed CTLs from normal human donors (Da Silva et al., 2001) , and memory responses have been detected in some CIN and cervical carcinoma patients but not in normal subjects (Ressing et al., 1995) . HLA restricted E7 peptides, and recombinant vaccinia viruses expressing E6 -E7 have been tested in Phase 1 clinical trials in terminal cervical cancer patients (Borysiewicz et al., 1996; Van Driel et al., 1999) and E7 peptides have been tested in high -grade cervical intra-epithelial neoplasia patients (Muderspach et al., 2000) . Generation of CTL, though generally disappointing in the cervical cancer patients, was seen in some cases, and some CIN patients showed lesion regression (Van Driel et al., 1999) . It is clear that more potent strategies for inducing long-lived E7-directed CTLs, preferably against a broad array of epitopes, are necessary for generating antitumour responses.
We have previously constructed replication-incompetent vaccine vectors or replicons derived from the Australian flavivirus Kunjin (KUN) by removing the KUN structural genes, and replacing them with a foreign gene Khromykh et al., 1998; Varnavski and Khromykh, 1999) . The replicons retain replicase genes which mediate RNA replication, and high-level foreign protein expression, but produce no progeny virus. Replicon-based vectors display exclusively cytoplasmic replication (reviewed in Khromykh, 2000) eliminating putative complications arising from nuclear splicing and chromosomal integration. Additionally, the inability of the replicon RNA to escape from the transfected/infected cell precludes vector spread in the vaccine recipient, rendering these vectors biologically safe. The small genome size makes replicon vectors easy to genetically manipulate, and minimises vector-directed immune responses. There is generally no preexisting immunity to KUN replicon vector determinants in humans in most of the world, except the northern parts of Australia where Kunjin virus is endemic. The replicon system offers the further advantage that replicons can be delivered either directly as naked RNA transcribed in vitro, or as plasmid DNA encoding replicon cDNA under the control of a mammalian expression promoter, or as RNA packaged into virus-like particles (VLPs).
The KUN replicon packaging system utilises a replicon expression vector derived from the unrelated Semliki Forest virus (SFV) for production of KUN structural proteins, thus eliminating potential problems associated with contamination of VLPs with infectious recombinant virus. A major advantage of the KUN replicon system is that unlike the highly cytopathic alphavirus replicon vectors commonly used in immunisation studies (Bredenbeek et al., 1993; Liljestrom and Garoff, 1991; Pushko et al., 1994 Pushko et al., , 1997 , KUN replicons are non-cytopathic, allowing prolonged expression of inserted genes in vivo (Varnavski et al., 2000) .
In the present study, we investigated the ability of the KUN replicon system to deliver a polyepitope, known to be immunogenic when delivered as DNA, which incorporated a CTL epitope of the HPV16 E7 protein. We show that although only moderate E7-directed T-cell responses were induced, since the E7 epitope appeared to be subdominant to other 'stronger' epitopes in the polyepitope, nonetheless, the recombinant KUN replicons protected against the growth of an E7-expressing epithelial tumour in immunised mice. Immune responses and tumour protection were more pronounced in mice immunised with replicon RNA packaged into VLPs than naked replicon RNA or plasmid DNA constructed to allow replicon RNA transcription in vivo.
Generically, the results demonstrate the efficacy of KUN replicon vectors for inducing protective immunity directed to a virally encoded human tumour-specific antigen, and suggest the possibility of simultaneous delivery of multiple protective epitopes. Specifically, there are implications for cervical cancer immunotherapy.
Results

Construction and cellular expression of KUN replicons encoding E7 CTL epitope
A polyepitope-encoding DNA vaccine, pSTMPDV, that elicits multiple simultaneous CTL responses when used to immunise mice has previously been reported (Thomson et al., 1998) . To create the immunogen used in the present study, we elected to delete an epitope from pSTMPDV and replace it with the H-2D b restricted CTL epitope RAHY-NIVTF (denoted RAH/D b ) (Feltkamp et al., 1995) (Fig. 1A, i , ii). In this, and in a repeat experiment (not shown), the former gave a somewhat better RAH/D b CTL response however, and was therefore selected for incorporation in the KUN replicon system (Fig. 1B) . We also measured CTL responses to polyepitope peptides SGP/D b and OVA/K b (Fig. 1A) .The responses were essentially similar to those reported previously for these epitopes using the unmodified polyepitope as immunogen (Thomson et al., 1996) KUN replicon RNA can be transcribed in vitro from plasmid DNA containing the bacteriophage SP6 promoter and delivered via transfection or injection as naked RNA . It can also be synthesised in vivo by cellular RNA polymerase II from transfected or injected plasmid DNA carrying a cytomegalovirus (CMV) promoter (Varnavski et al., 2000) (Fig. 1B) . In addition, KUN replicon can be packaged into VLPs (Khromykh et al., 1998) and delivered by infection. No matter how delivered, once in the cytoplasm, KUN replicon initiates self-replication, leading to multiple RNA copies and increased expression of the inserted sequence (Anraku et al., 2002; Varnavski et al., 2000) .
Plasmid Figs. 2A -C) . About 50% of cells were positive after transfection with DNAbased replicon, 80% were positive after electroporation with RNA-based replicon, and <1% were positive after infection with KUN replicon VLPs at the multiplicity of infection replication) ; sequences encoding the first 20 amino acids of KUN C (C20) and the last 22 amino acids of KUN E (E22) structural proteins; sequences encoding all the nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) with Leu at amino acid position 250 of the NS1 gene product; a unique cloning site (MluI); either a CMV promoter (DNA vector) or SP6 promoter (RNA vector) (to drive in vivo or in vitro expression, respectively); hepatitis delta virus anti-genomic ribozyme (HDVr) and the polyadenylation signal from SV40 [poly(A)] inserted downstream of the 3VUTR (to ensure production of KUN replicon RNA molecules with precise 3Vtermini for efficient initiation of replication); and the 2A autoprotease of foot-and-mouth disease virus (FMDV 2A) on both sides of the cloning site (to allow cytoplasmic release of the cloned polytope from the -KUN C20 and E22 peptides). KUN replicon VLP vectors are composed of the capped RNA transcript packaged by KUN core, envelope, and membrane structural proteins (not shown).
(moi) of 0.00025 used. At moi of 10, ca. 100% of cells infected with VLPs were positive (not shown), in agreement with our previous findings (Anraku et al., 2002; Harvey et al., 2003) . (Fig. 4B) . Immunisation with the higher dose of VLPs (2 Â 10 6 ) gave stronger responses to both epitopes than immunisation with the lower dose (5 Â 10 5 ) ( findings (above), immunisation with 2 Â 10 6 VLPs elicited a stronger SGP/D b -directed cytotoxic response than that induced by 5 Â 10 5 VLPs (Fig. 5D ). These data indicate that two immunisations with polyepitope-encoding KUN replicon DNA, replicon RNA, or replicon VLPs elicit functional CTL responses. À MP remained tumourfree at day 70 ( P = 0.0143) (Fig. 6) . The rate of tumour development was one fifth of that for unimmunised mice (hazard ratio = 0.2). This level of tumour protection was not significantly different ( P = 0.317) from that observed in mice immunised with a vast molar excess (30 Ag) of peptide encoding the minimal CTL epitope RAH/D b (Fig. 6 ). In mice immunised with KUN replicon RNA encoding E7 + OVA À MP, tumour growth was also retarded compared to unimmunised mice. Three of five mice remained tumourfree at 7 days, and one out of five mice remained tumourfree at 70 days ( P = 0.049) and the tumour development rate was ca. one half of that observed for unimmunised mice (hazard ratio = 0.59). To determine whether E7-directed tumour immunity persisted, immunised mice which were free of tumour at 70 days were re-challenged with tumour. À MP developed tumour (data not shown). In contrast, five out of five unimmunised identically challenged control mice developed tumour. Together, these data indicate that immunisation with KUN replicon expressing the E7 epitope protects against growth of an E7 tumour challenge, and suggests that the tumour protective immunity is long lived.
Discussion
In this study, we have constructed KUN virus replicons to deliver a CTL epitope of a viral oncoprotein (HPV16 E7) in the context of an immunogenic polyepitope. We have engineered the replicons to be administered either as naked RNA, plasmid DNA constructed to allow replicon RNA transcription in vivo, or RNA packaged into infectious but propagation-incompetent VLPs. Introduction of each of these into cells in vitro resulted in similar high levels of cytoplasmic expression (Fig. 2 and Anraku et al., 2002) . We demonstrate the generation of specific T-cell responses and protection against growth of an E7-expressing epithelial tumour in replicon-immunised mice. We found VLPs to be more effective than naked RNA or plasmid DNA. Protective immunity was induced although the E7 CTL epitope was subdominant in the context of other CTL epitopes in the polyepitope. The response was boosted by a second immunisation.
An important feature of the KUN replicon system is that modified KUN genetic material is self-replicating in cells (Anraku et al., 2002) , and, unlike other alphavirus replicons, KUN replicons are non-cytopathic , thus facilitating continuous and ongoing presentation of encoded immunogen to the recipient's immune system, with possible consequences for long-term generation of effector T-cell responses and maintenance of T-cell memory. We have previously shown that h-galactosidase expression from an intranasally administered KUNh-galactosidase DNA-based vaccine persisted undiminished in mouse lung epithelium for at least 2 months (Varnavski et al., 2000) . It may however be argued that cytopathicity as seen during infection with alphavirus replicons may foment a cytokine-mediated inflammatory milieu conducive to adaptive immune response induction.
The KUN replicon system offers further putative advantages. Unlike alphaviruses (Hill et al., 1997) , flaviviruses in general show no evidence of recombination between different viruses or virus strains, a feature of potential importance in vaccine recipients who may be infected with the same or other flaviviruses around the time of immunisation. Furthermore, the system for KUN VLP generation uses unrelated SFV for production of KUN structural proteins, which together with the specific design of the expression construct (Khromykh et al., 1998; Varnavski and Khromykh, 1999) precludes possible contamination of VLPs with infectious recombinant material. Additionally, the lack of ongoing production of KUN structural proteins and small genome size minimises the opportunity for development of vectordirected immunity, a possible drawback of other replicating viral vectors (e.g., vaccinia), which might preclude second or subsequent immunisation.
The above features not only ensure the effective and long-term delivery of epitopes, but would also predispose to the safety of the KUN replicon system for delivery of whole oncoproteins, for example, full-length E7. A further advantage is the relatively small size of the KUN replicon (in comparison to other viral vectors) which makes it easy to manipulate.
We elected to replace a OVA or a LCMV epitope in the original polyepitope with the E7 epitope because robust CTL killing directed to the former two epitopes was demonstrable in mice immunised with the parent polyepitope DNA (Thomson et al., J. Immunol. 1996) . The responses obtained to the E7 epitope in mice immunised with the engineered polytope were of lesser magnitude when compared with OVA or LCMV epitopes and with some other epitopes in the polyepitope (Figs. 3 and 4) . The 'weak' response to the E7 epitope was maintained irrespective of whether the polyepitope was delivered as conventional DNA, KUN replicon DNA, KUN replicon RNA, or KUN replicon VLPs (Fig. 4) . While positioning of an epitope within a DNA polyepitope may affect the magnitude of the CTL response to that epitope (Ishioka et al., 1999) , the rules governing this phenomenon are not worked out. It is well established that a hierarchy of CD8 T-cell responses from subdominant to dominant can be seen following polyepitope vaccination (Anraku et al., 2002; Le et al., 2001) , though whether dominant responses effectively suppress or interfere with induction of less dominant responses remains controversial. While deletion of more dominant epitopes in our polyepitope may improve the response to the E7 epitope, there is data to show that removal of a dominant epitope did not improve responses to a subdominant epitope within the same polyepitope vaccine (Suhrbier, 2002) . Alternatively, the lower response we report to the E7 epitope may simply reflect that the E7 epitope is constitutively not a 'strong' epitope (Doan et al., 1998; Feltkamp et al., 1995) rather than its position within the engineered polyepitope.
In spite of the weak response to the E7 epitope RAH/D b , immunisation with KUN replicon VLPs encoding E7 + OVA À MP completely protected 80% of mice against a dose of E7-expressing tumour cells which gave 100% tumour incidence in unimmunised mice (Fig. 6) . Additionally, immunisation with E7 + OVA À MP KUN replicon as naked RNA delayed tumour growth in some mice, and completely protected one (of five) mice (Fig. 6 ). All completely protected mice remained tumour-free 70 days after challenge. Furthermore, they retained tumour immunity because all rejected a second TC-1 tumour challenge at this time. These data emphasise the efficacy of induction of tumour protection by the KUN replicon system encoding a tumour antigen, and further suggest the induction of a long-term memory response. Other studies in our laboratory indicate that specific memory responses in mice immunised once with KUN replicon encoding a murine polyepitope or HIV-1 gag may be recalled undiminished until at least 6 months by in vitro restimulation of splenocytes (Harvey et al., 2003) . We surmise that the long-lived expression due to the noncytopathic infection unique to the KUN replicon system contributes to the observed long-lived memory.
We have not excluded the possibility that although the measured T-cell response directed to RAH/D b is weak compared to SGP/D b , the former T cells could have high avidity, which perhaps might explain their efficacy in tumour protection. Furthermore a differential expansion of RAH/D b -and SGP/D b -specific T cells without effector function might contribute to the discrepancy between T-cell responses measured in vitro and in vivo. Overall, our findings are congruent with other studies indicating that effective protection against certain diseases may be adequately mediated by subdominant memory responses that are amplified after challenge (Le et al., 2001; Moss et al., 1996) .
We have experiments planned to investigate whether immunisation with recombinant KUN replicons expressing the E7 CTL epitope will have a therapeutic effect on E7-associated carcinomas which develop in mice expressing an E7 transgene specifically in the basal and suprabasal cells of squamous epithelium (Herbert et al., 1996) . These mice constitute a model for HPV-associated human squamous carcinoma of the uterine cervix (Frazer et al., 1995) .
The above results, and our previous data (Anraku et al., 2002) , demonstrating concomitant CTL responses to many epitopes encoded by KUN replicon, suggest the possibility of broad-based therapy afforded by a polyepitope constructed to express multiple HPV epitopes targeting other oncogenic HPV genotypes and HLA restriction elements. Such a vaccine would be applicable to a diversely HPVinfected and out-bred human population. Because repliconinitiated tumour protection is mediated by CTLs directed to tumour epitopes (Cheng et al., 2002) , our observation that ostensibly weak responses translate into strong tumour protection may be of particular relevance for humans in which E7 HLA-restricted epitopes do not elicit powerful CTL responses either in E7-expressing cervical carcinoma patients (Ressing et al., 1995) or in recipients of E7 peptide vaccines (Van Driel et al., 1999) .
In agreement with our previous findings (Anraku et al., 2002) , the in vitro T-cell responses induced by KUN replicon VLP and KUN replicon RNA were superior to that induced by conventional DNA immunisation (Fig. 4B) .
[Note that in preliminary experiments, we determined the optimal delivery route for each. In the present study, we compared vaccine efficacy using the optimal route for RNA (im), DNA (im), VLPs (ip), and peptide (sc).] While we have previously reported (Anraku et al., 2002 ) that comparable levels of T-cell induction to another encoded immunogen required a 1000-fold higher dose of conventional plasmid DNA vaccine compared to KUN replicon DNA, the difference was not so large in the present study. The response induced by KUN replicons may depend on the nature of the encoded immunogen, as it does for DNA based alphavirus replicons (Berglund et al., 1997; Hariharan et al., 1998) . It is noteworthy that KUN replicon encoding E7 + OVA À MP elicited somewhat better T-cell responses (Figs. 4B, 5 ) when administered as naked RNA than as plasmid cDNA.
We have previously reported that 5-to 10-fold higher amounts of KUN-specific RNAs were produced in cells transfected with a plasmid DNA encoding replication-competent KUN replicon RNA compared with a plasmid DNA encoding a replication-deficient KUN replicon RNA (Varnavski et al., 2000) . Increased levels of KUN RNA correlated with increase KUN protein production in cells measured by immunofluorescence Khromykh et al., 1998) . These findings likely contribute to the enhanced responses elicited to repliconencoded antigen versus antigen encoded in a conventional nonreplicating nucleic acid vaccine reported in our present and previous (Anraku et al., 2002) studies. KUN replicon VLPs encoding E7 + OVA À MP elicited stronger T-cell responses to polyepitope [measured either as ex vivo IFNg ELISPOTS (Fig. 4) or as 51 Cr-release CTL after restimulation in vitro (Fig. 5)] , and better tumour protection, than KUN replicon RNA (Fig. 6) . This suggests that VLPs may be the preferred mode of replicon delivery. The observed superiority of KUN replicon VLPs likely also relates to enhanced delivery of replicon RNA to APCs using this vaccine modality compared with KUN replicon administered as plasmid DNA or naked RNA. The encapsidation of replicon RNA into VLPs by the corresponding viral structural proteins prevents RNA degradation and may provide a more efficient delivery of replicon RNA via infection, which mimics the normal virus entry pathway. Immunofluoresecence analysis of BHK21 cells with KUN anti-NS3 antibody showed the highest percentage of positive cells after infection with KUN replicon VLPs (ca. 100% at moi = 10) and the least after transfection with plasmid DNA-based replicon (ca.50%).
Significant tumour protection afforded by naked RNA immunisation has been reported in various tumour models (Anraku et al., 2002; Ying et al., 1999) . Although naked RNA offers advantages over DNA in avoiding potential DNA integration, and over VLPs in avoiding putative VLPdirected antibody and CTL induction, naked RNA vaccines have the disadvantages of instability and difficulties of preparation.
Effective booster immunisation using a second inoculation with the same virus vector-based vaccine usually demands that the primary immunisations did not lead to the production of neutralising antibodies. In another study, we have specifically investigated whether there was any significant neutralising antibody response to KUN envelope VLP protein after two immunisations with KUN VLPs encoding a foreign protein (HIV gag). We showed that although VLP infectivity was completely neutralised by anti-VLP monoclonal antibody, sera from mice immunised twice with KUNgag VLPs showed no significant neutralising activity above that recorded for sera from unimmunised (control) mice (Harvey et al., 2003) . Additionally, preexisting CD8+ T-cells specific for vaccine vector or encoded vaccine antigen do not usually influence the efficacy of CTL induction to encoded antigen following subsequent immunisation (Sherritt et al., 2000) . These observations indicate that repeated immunisations with KUN VLPs to boost protective responses to encoded antigen are feasible.
The polyepitope response following replicon VLP immunisation was dose dependent (Fig. 4B) , with 2 Â 10 6 VLPs being more effective than 5 Â 10 5 (Figs. 4B and 5). Our most recent data show that even higher CTL responses can be induced by increasing the VLP dose further (not shown). Daemen et al. (2002) investigated the immunotherapeutic potential of recombinant SFV alphavirus replicons expressing full-length HPV16 E6 and E7, and reported somewhat less robust tumour protection than we found in our studies (40% of their mice were tumour-free after three immunisations with a 10-fold higher VLP dose, using a 10-fold less TC-1 tumour cell challenge, than used in our experiments). While differences in experimental conditions (e.g., number of moles of immunogenic epitope available, the cellular tropism of alphavirus VLPs versus KUN VLPs, etc.) will have determined outcome, nonetheless, the results underscore the comparative high efficacy of the KUN replicon VLPs at inducing tumour protection. Similar or greater levels of E7-directed tumour protection have been recorded following immunisation with Venezuelan Equine Encephalitis replicon VLPs and Sindbis virus replicon VLPs encoding fulllength E7 protein. The latter required E7 protein fused to a Herpes simplex tegument protein which facilitated the spread of E7 antigen to neighbouring cells following apoptosis of cells 'infected' by immunisation (Cheng et al., 2002) .
We did not investigate the requirement for CD4+ T-'help' or CD40 dependency in induction of CTL responses by E7 epitope recombinant KUN replicon. There are data to suggest that CTL induction by the polyepitope protein is Thelp independent (Thomson et al., 1998) . Furthermore, RAH/D b -directed CD8+ CTL induction by peptide (Doan et al., 1998) or whole E7 protein does not require concomitant CD4+ T-cell activation. However, in those cases where CD4+ T help might be required, for example, for HLA A*0201-restricted E7 CTL epitopes (Ressing et al., 2000) , or in the rejection of established tumours , 'help' may be provided from T-helper epitopes within the KUN nonstructural proteins, or by incorporating a universal T-helper epitope encoding sequence in the inserted gene (Ressing et al., 2000) .
In conclusion, we show that incorporation of a HPV16 E7 CTL epitope into a polyepitope encoded by a KUN replicon vector used for immunisation induced E7-directed T-cell responses as measured by g-IFN secretion and cytotoxicity, and afforded mice with protection against challenge with an E7-expressing epithelial tumour. We found that replicon RNA packaged into VLPs was more effective than naked replicon RNA or plasmid cDNA constructed to allow replicon RNA transcription in vivo. Generically, the results demonstrate the efficacy of KUN replicon vectors for inducing immunity against multiple inserted epitopes, and protective immunity against a clinically relevant viral antigen subdominant in the context of co-inserted epitopes. Specifically, there are implications for the generation of effective therapeutic immunity for HPV-associated neoplastic disease.
Materials and methods
Plasmids
Conventional DNA plasmids, pE7 + OVA À MP and pE7 + LCMV À MP, were created by site-directed mutagenesis of pSTMPDV (Thomson et al., 1998) which encodes a mouse polytope, comprising 10 minimal CTL epitopes and one B cell epitope (Fig. 1A) . Substitution primers were designed to introduce the H-2D b restricted CTL epitope of HPV16E7 ( 49 RAHYNIVTF 57 ) (Feltkamp et al., 1995) at either the OVA or LCMV site. A recombination PCR approach (Jones and Howard, 1991) was used, so primer pairs had 5V ends with overlapping sequences encoding the mutation (underlined) and 3V ends complementary to the template adjacent to the deletion site (shown in bold). For the OVA À mutation, primers (5V !3V ) were: AGG GCC-CAC TAC AAC ATC GTG ACC TTC ACC TAC CAG AGG ACC AGG (forward); GAA GGT CAC GAT GTT-GTA GTG GGC CCT CAT AGC GTC CAT GTT CTC (reverse). For the LCMV À mutation, primers (5V !3V ) were: AGG GCC CAC TAC AAC ATC GTG ACC TTC CCT AGG AAC AAC CTG GT (forward); GAA GGT CAC-GAT GTT GTA GTG GGC CCT GAT CTC ACC GAC GAT GGC (reverse). Linear PCR product with doublestranded homologous ends was purified with a QIAquick gel extraction kit (QIAGEN, Clifton Hill, VIC, Australia) and used to transform competent E. coli (MaxEfficiency DH5a, Invitrogen, Melbourne, VIC, Australia). Plasmid DNA was sequenced to confirm the mutation before the polytope was subcloned into KUN replicon vectors. The polytope sequence was amplified from pE7 + OVA À MP template by high-fidelity PCR with Pfu DNA polymerase and subcloning primers designed to introduce MluI sites (shown in bold) at both ends. Primers (5V !3V ) were: GCG ACG CGT CTA GAG CCA GCA ACG AGA A (Mpt-F); GTA ACG CGT CTA AGT CCT CGG GGC CGG (Mpt-R). The PCR product was digested with MluI and cloned into replicon DNA and RNA vectors (Fig. 1B) . Restriction enzyme analysis as well as DNA sequencing confirmed the presence and orientation of the polyepitope.
Cell lines and peptides
Cells were cultured in DMEM (Invitrogen) with 20 mM HEPES, 2 mM L-glutamine (GlutaMax I, Invitrogen), 1 mM sodium pyruvate, 100 IU/ml penicillin, 100 Ag/ml streptomycin, 50 AM 2-mercaptoethanol, and 10% foetal bovine serum. Baby hamster kidney cells (BHK21) were used for replicon expression studies and Vero cells for titration of VLPs. The EL4.A2 target cell line (H-2 b thymoma) (Doan et al., 1998) and the TC-1 cell line (primary lung epithelial cells from C57BL/6 mice transformed with HPV16 E6 and E7 and activated ras oncogene) (Lin et al., 1996) 
DNA and RNA transfection, immunofluorescence analysis
For DNA transfections, BHK21 cell monolayers were transfected with 0.4 Ag plasmid DNA, using Lipofectamine Plus (Invitrogen), as described by the manufacturer. For RNA transfections, RNA was transcribed in vitro from XhoI-linearised template DNA using SP6 RNA polymerase (Roche, Castle Hill, NSW, Australia) and capping analogue, m 7 G(5V)ppp(5V)G (New England BioLabs, Beverly, MA) and then electroporated into BHK21 cells as described previously . After 48 h, cells were fixed in cold acetone and analysed for expression of KUN NS3 protein by indirect immunofluorescence (IF) as described previously .
Preparation of DNA and RNA vaccines DNA vaccines were prepared using an EndoFree plasmid mega kit (QIAGEN) and quality assured by agarose gel electrophoresis. RNA vaccines were prepared using a commercially available kit (mMessage mMachine SP6 transcription kit, Ambion, Austin, TX) and the recommended protocol for long transcripts at a CAP/GTP ratio of 2:1. Transcribed RNA was used after DNase treatment, but without further purification and was quality assured by denaturing agarose gel electrophoresis.
Preparation of VLP vaccines
KUN replicon VLPs were produced as described previously Khromykh et al., 1998; Varnavski and Khromykh, 1999) by sequential transfection of BHK21 cells with in vitro transcribed RNA. Briefly, BHK21 cells were electroporated in the presence of KUN replicon RNA using a Gene Pulser II and Pulse Controller (Bio-Rad, Regents Park, NSW, Australia), then cultured for 32 h. Cells were then trypsinised and electroporated again under the same conditions, with SFV replicon RNA expressing the KUN structural proteins (SFV MEC105) (Khromykh et al., 1998) . After a further 40 h in culture, medium was collected, clarified by low-speed centrifugation, and VLPs were snap-frozen in dry-ice/ethanol, either immediately or after purification on a discontinuous sucrose density gradient. VLP titre was determined by infecting Vero cell monolayers with a series of decimal dilutions and performing immunofluorescence and analysis after 30 to 40 h. Typically, the titre of unpurified VLPs was 7 Â 10 6 IU/ml.
Immunisation of mice
H-2 b (A2.1Kb) and H-2 d (BALB/c) female mice (6 to 8 weeks) were supplied by Animal Resources Centre (Perth, WA, Australia) and maintained under specific pathogen-free conditions. All experiments were conducted with approval from the University of Queensland (Australia), Animal Ethics Committee. DNA vaccines (100 Ag resuspended in 100 Al of 0.9% NaCl) or RNA vaccines (50 Ag diluted to 100 Al with nuclease-free 0.9% NaCl, 10 mM HEPES) were injected intramuscularly, using 50 Al in each quadriceps muscle, under anaesthesia with ketamine/xylazine. The doses were chosen from preliminary experiments to give maximal CTL responses for these vaccines. VLP vaccines (5 Â 10 5 or 2 Â 10 6 IU in <0.5 ml) were injected intraperitoneally. Mice were immunised at 28 and 14 days before immune status evaluation. Multi-peptide vaccines (30 Ag each peptide, 0.25 Ag tetanus toxoid, 10 Ag Quil A, diluted in PBS to 100 Al) were injected once subcutaneously at the tail base 10 days before immune status evaluation.
T-cell assays for IFN-c release and cytotoxicity
Epitope-specific gamma interferon (IFN-g)-secreting spleen cells were enumerated ex vivo by an enzyme-linked immunospot (ELISPOT) assay with minimal CD8 + T-cell epitope peptides, essentially as described previously (Le et al., 2001) . Microwell plates (MultiScreen-HA, Millipore, North Ryde, NSW, Australia) were coated with capture antibody (rat anti-mouse IFN-g, clone RA-6A2, BD PharMingen, San Diego, CA), blocked with DMEM 10% FBS, and washed. Serial dilutions of spleen cells, starting at 10 6 / well were added, with 100 U/ml recombinant human interleukin-2 (Sigma, Castle Hill, NSW, Australia) and incubated with 10 Ag/ml peptide or without, for 15 -18 h at 37 jC. The cells were then lysed, the plates washed, and detection antibody (biotinylated anti-mouse IFN-g, clone XMG 1.2, BD PharMingen) was added for 2 h. at 37 jC. After further washing, plates were developed using streptavidin-alkaline phosphatase (BD PharMingen) and BCIP-NBT substrate (Sigma FAST 5-bromo-4-chloro-3-indolylphosphate-nitroblue tetrazolium). IFN-g spots were counted using an AID EliSpot reader system. Results were calculated as IFN-gpositive cells/10 6 spleen cells. Activation index was defined as the mean (n = 3) frequency of spots with peptide, divided by the frequency of spots without peptide and was considered significant if greater than two.
Epitope specific cytotoxicity of spleen cells was determined by 51 Chromium ( 51 Cr)-release CTL assay as described (Doan et al., 1998) . Ex vivo spleen cells from immunised mice were depleted of professional APCs by plastic adherence and restimulated by co-culture with peptide-loaded lymphoblasts at a ratio of 10:1. Lymphoblasts were spleen cells that had been activated for 3 days with 25 Ag/ml lipopolysaccharide (Sigma) and 7 Ag/ml dextran sulphate, then irradiated (3000 rad) and incubated with 10 Ag/ml individual peptide for 90 min. After 6 days restimulation, effector cells were reacted at the specified effectorto-target cell (E:T) ratios with 51 Cr-labelled EL4.A2 target cells which had been loaded with 10 Ag/ml peptide, or without. After 4-6 h incubation, radioactivity (cpm) in 100 Al of cell-free supernatant was determined by gamma counting. Percentage of cytotoxicity F standard deviation was calculated using the formula (E À S) / (T À S) Â 100, where E represents cpm released in the presence of effector cells, S represents spontaneous cpm with medium only, and T represents total cpm in the presence of 5% sodium dodecyl sulphate. S values were always less than 15% of T. Peptide specific cytotoxicity was defined as the difference between the mean (n = 3) cytotoxicity against targets with peptide and without.
Tumour protection assay
Groups of H-2 b mice (n = 5) were immunised twice before TC-1 cells (2 Â 10 5 in 0.1 ml Hank's buffered salt solution) were injected subcutaneously on the left flank using a 21 gauge needle. (The tumour dose was predetermined by titration experiments to discern a minimal dose giving rise to tumour in 100% of unimmunised mice.) Tumour growth was monitored every 3 days, and mice were euthanised when tumour volume exceeded 1000 mm 3 . The time when mice developed palpable tumour was noted and represented in Kaplan -Meier survival curves (Lemeshow, 1999) . Differences between the curves were calculated using the log rank statistic and a hazard ratio at a 95% confidence interval. At 70 days postchallenge, the tumour-free mice were re-challenged with TC-1 cells injected subcutaneously on the right flank.
Unimmunised mice received the same number of cells and served as a control.
